Assignee
MINERVA BIOTECHNOLOGIES CORP
US·30 granted patents·55 pending applications·115 citations·filing 1999–2025
Top patents by PatentIndex Score
85 records- 0196US12115192B2Chimeric antigen receptor compositions and methods for treating MUC1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Oct 15, 2024·3 cites·39 claims
- 0296US12049618B2Method for making pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2020·Granted Jul 30, 2024·3 cites·18 claims
- 0396US11976295B2Media for stem cell proliferation and inductionMINERVA BIOTECHNOLOGIES CORP·Filed 2023·Granted May 7, 2024·4 cites·19 claims
- 0495US12351646B2Diagnostic methods using anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Jul 8, 2025·1 cites·16 claims
- 0595US12195728B2Method for making pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Jan 14, 2025·1 cites·6 claims
- 0695US12049514B2Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jul 30, 2024·3 cites·16 claims
- 0795US12037413B2Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jul 16, 2024·3 cites·28 claims
- 0895US12006371B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Granted Jun 11, 2024·3 cites·29 claims
- 0995US11976132B2Diagnostic methods using anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2019·Granted May 7, 2024·5 cites·18 claims
- 1095US11897967B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Granted Feb 13, 2024·3 cites·30 claims
- 1194US12202799B2Agents for differentiating stem cells and treating cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Jan 21, 2025·2 cites·18 claims
- 1294US11746159B2Humanized anti-MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2016·Granted Sep 5, 2023·8 cites·13 claims
- 1392US11931347B2Method of screening for agents for differentiating stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2016·Granted Mar 19, 2024·5 cites·21 claims
- 1490US10703821B2Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptorMINERVA BIOTECHNOLOGIES CORP·Filed 2014·Granted Jul 7, 2020·5 cites·15 claims
- 1590US9932407B2Stem cell enhancing therapeuticsMINERVA BIOTECHNOLOGIES CORP·Filed 2015·Granted Apr 3, 2018·8 cites·38 claims
- 1689US11560435B2MUC1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2019·Granted Jan 24, 2023·4 cites·17 claims
- 1789US10724027B2Method for making pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2013·Granted Jul 28, 2020·4 cites·6 claims
- 1888US12104170B2Methods for deriving dopaminergic neurons from pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Granted Oct 1, 2024·2 cites·37 claims
- 1988US11702483B2Method of treating an NME7 expressing cancer with a peptideMINERVA BIOTECHNOLOGIES CORP·Filed 2018·Granted Jul 18, 2023·2 cites·7 claims
- 2088US8344113B2Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2010·Granted Jan 1, 2013·8 cites·13 claims
- 2188US2025067746A1Methods for culturing stem and progenitor cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2287US11591565B2Media for stem cell proliferation and inductionMINERVA BIOTECHNOLOGIES CORP·Filed 2014·Granted Feb 28, 2023·5 cites·19 claims
- 2387US2024277803A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2486US2025066505A1Diagnostic methods using anti-muc1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2584US2025026853A1Humanized anti-muc1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2681US12415868B1Anti-NME antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Granted Sep 16, 2025·0 cites·9 claims
- 2781US2024409515A1Agents for differentiating stem cells and treating cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2881US2024424025A1Chimeric antigen receptor compositions and methods for treating muc1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 2980US2024307359A1Method of screening for agents for differentiating stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3080US2024392038A1Anti-nme antibody and method of treating cancer or cancer metastasisMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3180US2024294590A1Nucleic acid encoding genetically engineered growth factor variantsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3279US2022193270A1Method for enhancing tumor growthMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 3379US2024261406A1Chimeric antigen receptor compositions and methods for treating muc1* diseasesMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3478US7615340B2Electronic detection of interaction and detection of interaction based on the interruption of flowMINERVA BIOTECHNOLOGIES CORP·Filed 2001·Granted Nov 10, 2009·11 cites·58 claims
- 3578US2022218846A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 3676US2022089779A1Nme inhibitors and methods of using nme inhibitorsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 3776US2024299507A1Humanized anti-muc1* antibodies and direct use of cleavage enzymeMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 3876US2022252604A1Methods for culturing stem and progenitor cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 3975US12479928B2Anti-cancer peptideMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Granted Nov 25, 2025·0 cites·20 claims
- 4074US8349853B2Compositions and methods of treatment of cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2002·Granted Jan 8, 2013·2 cites·41 claims
- 4174US2025121088A1Anti-muc1* antibody drug complexes and uses thereofMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4273US2023049461A1Nme variant species expression and suppressionMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Application pending·0 cites
- 4372US2023295340A1Muc1* antibodiesMINERVA BIOTECHNOLOGIES CORP·Filed 2022·Application pending·0 cites
- 4472US2025019651A1Methods for deriving dopaminergic neurons from pluripotent stem cellsMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4571US2022202786A1Methods for treatment of cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2021·Application pending·0 cites
- 4670US2024247229A1Media for stem cell proliferation and inductionMINERVA BIOTECHNOLOGIES CORP·Filed 2024·Application pending·0 cites
- 4768US9649312B2Compositions and methods of treatment of cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2012·Granted May 16, 2017·0 cites·2 claims
- 4867US7700715B2Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2001·Granted Apr 20, 2010·5 cites·12 claims
- 4967US2025276016A1Chimeric antigen receptor and il-18 receptor compositions and methods of use thereinMINERVA BIOTECHNOLOGIES CORP·Filed 2023·Application pending·0 cites
- 5066US2017246168A1Compositions and methods of treatment of cancerMINERVA BIOTECHNOLOGIES CORP·Filed 2017·Application pending·0 cites
Showing the top 50 of 85 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MINERVA BIOTECHNOLOGIES CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →